Erste Asset Management GmbH bought a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 51,300 shares of the company's stock, valued at approximately $2,096,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IONS. Teachers Retirement System of The State of Kentucky boosted its holdings in Ionis Pharmaceuticals by 70.6% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 24,083 shares of the company's stock worth $1,044,000 after acquiring an additional 9,965 shares in the last quarter. Tidal Investments LLC purchased a new stake in Ionis Pharmaceuticals in the first quarter valued at approximately $885,000. Great Point Partners LLC purchased a new stake in Ionis Pharmaceuticals in the second quarter valued at approximately $15,728,000. DRW Securities LLC purchased a new stake in Ionis Pharmaceuticals in the second quarter valued at approximately $2,429,000. Finally, Charles Schwab Investment Management Inc. boosted its position in Ionis Pharmaceuticals by 8.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,443,020 shares of the company's stock valued at $57,807,000 after buying an additional 114,914 shares during the last quarter. 93.86% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on IONS. JPMorgan Chase & Co. lifted their price target on Ionis Pharmaceuticals from $50.00 to $55.00 and gave the company a "neutral" rating in a research report on Monday, August 26th. Wells Fargo & Company decreased their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating on the stock in a research note on Thursday, November 7th. Needham & Company LLC reissued a "buy" rating and issued a $60.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, November 7th. Royal Bank of Canada reissued an "outperform" rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, September 26th. Finally, Piper Sandler reduced their price target on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating on the stock in a research report on Thursday, November 14th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Ionis Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $60.65.
Get Our Latest Research Report on Ionis Pharmaceuticals
Ionis Pharmaceuticals Trading Up 3.7 %
IONS stock traded up $1.34 during midday trading on Wednesday, reaching $37.15. 1,372,452 shares of the company's stock traded hands, compared to its average volume of 1,331,072. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $33.33 and a fifty-two week high of $54.44. The business has a 50-day moving average price of $37.85 and a two-hundred day moving average price of $42.36. The company has a market capitalization of $5.87 billion, a P/E ratio of -15.23 and a beta of 0.35.
Insider Buying and Selling at Ionis Pharmaceuticals
In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 6,630 shares of the company's stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total value of $252,271.50. Following the transaction, the chief executive officer now directly owns 167,393 shares of the company's stock, valued at $6,369,303.65. This represents a 3.81 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Eric Swayze sold 1,194 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total value of $45,276.48. Following the completion of the transaction, the executive vice president now owns 33,713 shares of the company's stock, valued at approximately $1,278,396.96. The trade was a 3.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 7,877 shares of company stock valued at $299,578 over the last 90 days. 2.71% of the stock is owned by corporate insiders.
About Ionis Pharmaceuticals
(
Free Report)
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
Further Reading
Before you consider Ionis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.
While Ionis Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
